Literature DB >> 26293078

Extreme Hyperlactatemia After Heart Transplantation: One Center's Experience.

Y C Hsu1, C H Hsu1, G S Huang1, C C Lu2, Z F Wu1, Y T Tsai3, C Y Lin3, Y C Lin4, C S Tsai3, T C Lin5.   

Abstract

INTRODUCTION: Hyperlactatemia may occur early after cardiac surgery and is correlated with prognosis. This study was conducted to analyze the perioperative variables and postoperative outcomes among heart transplant recipients with extremely high lactate levels (>15 mmol/L).
METHODS: The single-center medical records of heart transplantation from June 2006 to May 2013 were retrospectively reviewed for patient characteristics, perioperative hemodynamic variables, arterial blood gas analysis data, and postoperative mortality.
RESULTS: Among 58 consecutive heart transplant recipients, lactate levels over the detectable upper limit (>15 mmol/L) were identified in 12 patients after intensive care unit admission, with peak time at 1.9 ± 2.0 (range 0-6.1) hours. The maximal preoperative lactate level was 3.1 mmol/L, and most (11/12) postoperative lactate levels returned to <4 mmol/L at 27.5 ± 12.8 hours after surgery (range 15-58, median 24), displaying a trend toward delayed extubation time in 10 recipients (P < .01). Blood glucose levels elevated significantly from preoperative 148.9 ± 45.2 to 375.7 ± 96.9 mg/dL at peak lactate level (P < .01). Four patients died in the ICU (range 5-32 days), 4 died after discharge (range 5-57 months), with 6 in total surviving over 1 year.
CONCLUSION: Extreme hyperlactatemia commonly occurred early after heart transplantation and mostly recovered within 30 hours; however, with delayed extubation time after operation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26293078     DOI: 10.1016/j.transproceed.2015.02.027

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Postoperative hyperlactatemia and serum lactate level trends among heart transplant recipients.

Authors:  Anna Kędziora; Karol Wierzbicki; Jacek Piątek; Hubert Hymczak; Izabela Górkiewicz-Kot; Irena Milaniak; Paulina Tomsia; Dorota Sobczyk; Rafal Drwila; Boguslaw Kapelak
Journal:  PeerJ       Date:  2020-02-06       Impact factor: 2.984

2.  The Effect of Supplemental Cardioplegia Infusion before Anastomosis in Patients Undergoing Heart Transplantation with Long Ischemic Times.

Authors:  Hong Rae Kim; Sung-Ho Jung; Junho Yang; Min Su Kim; Tae-Jin Yun; Jae-Joong Kim; Jae Won Lee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2020-12-05

3.  Isoflurane compared with fentanyl-midazolam-based anesthesia in patients undergoing heart transplantation: A retrospective cohort study.

Authors:  Che-Hao Hsu; Yung-Chi Hsu; Go-Shine Huang; Chih-Cherng Lu; Shung-Tai Ho; Wen-Jinn Liaw; Yi-Ting Tsai; Chih-Yuan Lin; Chien-Sung Tsai; Tso-Chou Lin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

4.  Postoperative Serum Lactate Levels for In-Hospital Mortality Prediction Among Heart Transplant Recipients.

Authors:  Anna Kędziora; Karol Wierzbicki; Jacek Piątek; Hubert Hymczak; Izabela Górkiewicz-Kot; Irena Milaniak; Paulina Tomsia; Dorota Sobczyk; Rafał Drwiła; Bogusław Kapelak
Journal:  Ann Transplant       Date:  2020-05-26       Impact factor: 1.530

5.  Cerebral Oximetry-Monitored Nitroglycerin Infusion and Tissue Perfusion during Rewarming of Cardiopulmonary Bypass in Cardiac Surgery: A Prospective Randomized Trial.

Authors:  Jia-Lin Chen; Yung-Chi Hsu; Go-Shine Huang; Chih-Yuan Lin; Hung-Yen Ke; Po-Shun Hsu; Chi-Hsiang Chung; Chien-Sung Tsai; Tso-Chou Lin
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

6.  Early postoperative hemodynamic instability after heart transplantation - incidence and metabolic indicators.

Authors:  Anna Kędziora; Jacek Piątek; Hubert Hymczak; Grzegorz Wasilewski; Bartłomiej Guzik; Rafał Drwiła; Bogusław Kapelak; Dorota Sobczyk; Janusz Konstanty-Kalandyk; Karol Wierzbicki
Journal:  BMC Anesthesiol       Date:  2021-10-02       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.